Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Lawrence Blonde Julio Rosenstock Stephano Del Prato Robert R HenryNaim ShehadehJuan Pablo FriasElisabeth NiemoellerElisabeth SouhamiChen JiVanita R Aroda

Published in: Diabetes care (2019)

Switching to iGlarLixi improves glucose control for patients with type 2 diabetes insufficiently controlled on a maximum tolerated dose of a GLP-1 RA plus oral antihyperglycemic agents.

Keyphrases

rheumatoid arthritis
type diabetes
disease activity
ankylosing spondylitis
interstitial lung disease
cardiovascular disease
glycemic control
clinical trial
stem cells
insulin resistance
blood pressure
metabolic syndrome
systemic sclerosis
skeletal muscle
cell therapy
double blind